Advanced medical devices are playing an important role in diagnosis and treatment in clinical settings. However, it is extremely difficult for these devices, especially for high-risk therapeutic medical devices such as artificial organs, to be put into practical use from their developmental stage. This difficulty is mainly derived from immature systems and environments for smooth and seamless processing from research and development to clinical application and commercialization. There are various hazards and obstacles in this process including national character and public trends such as points-off system and medical bashing, negative company posture and refusal of materials supply against possible damages caused by PL and harmful rumors, insufficiency in human resources and investments for research and development, excessive reduction of national medical expenditure, immaturity of venture capitals for appropriate evaluation of investments, and regulatory affairs such as translational research, clinical trial and government approval. This paper describes the details of these problems, as well as countermeasures, based on the author's experiences in research and development, clinical application, and commercialization of advanced circulatory medical devices and artificial organs.
View full abstract